---
title: 'ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive
  NSCLC With Prior ALK Inhibitor Resistance'
date: '2024-09-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39309618/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240923200302&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: ALKTERNATE revealed feasibility with a novel alternating
  ALK inhibitor strategy in ALK-positive NSCLC. Results support progressing inquiry
  into this approach and propose a flexible design with drug(s) selected and alternating
  time frames, informed by real-time plasma profiling. Moving this concept to treatment
  naive may also optimize ...'
disable_comments: true
---
CONCLUSIONS: ALKTERNATE revealed feasibility with a novel alternating ALK inhibitor strategy in ALK-positive NSCLC. Results support progressing inquiry into this approach and propose a flexible design with drug(s) selected and alternating time frames, informed by real-time plasma profiling. Moving this concept to treatment naive may also optimize ...